Study #2022-0135
RYZ101-301_Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care (SoC) Therapy in Subjects with Inoperable, Advanced, Somatostatin Receptor Expressing (SSTR+), Well-differentiated Gastro-enteropanc
MD Anderson Study Status
Enrolling
Treatment Agent
Description
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Study phase:
Physician name:
Arvind Nageshwara Vijaya Dasari
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-855-581-8877
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.